Holen Sie sich die Stockscreener-App
428.05
1.20%
-6.02
Schlusskurs vom Vortag:
$434.07
Offen:
$429.9
24-Stunden-Volumen:
66,020
Relative Volume:
0.06
Marktkapitalisierung:
$56.07B
Einnahmen:
$3.21B
Nettoeinkommen (Verlust:
$43.57M
KGV:
1,779.83
EPS:
0.2405
Netto-Cashflow:
$221.36M
1W Leistung:
-9.88%
1M Leistung:
-6.02%
6M Leistung:
+65.34%
1J Leistung:
+58.87%
1-Tages-Spanne:
$425.56
$431.50
1-Wochen-Bereich:
$425.56
$482.73
52-Wochen-Spanne:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
427.76 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.59 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.71 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
834.81 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.25 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Alnylam (NASDAQ: ALNY) to present Nov 10 & Nov 19 at UBS and Jefferies; live webcasts - Stock Titan
Alnylam to Webcast Presentations at Upcoming November Investor Conferences - FinancialContent
Royalty Pharma Acquires $310 Million Royalty Interest in Alnylam's AMVUTTRA from Blackstone Life Sciences - Quiver Quantitative
Hussman Strategic Advisors Inc. Sells 2,100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Why global investors buy Alnylam Pharmaceuticals Inc. (DUL) stock2025 Volatility Report & Weekly High Momentum Picks - newser.com
Amalgamated Bank Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Assetmark Inc. Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Regression analysis insights on Alnylam Pharmaceuticals Inc. performancePortfolio Gains Report & Daily Risk Controlled Trade Plans - newser.com
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumWeekly Stock Report & Real-Time Sentiment Analysis - newser.com
Will Alnylam Pharmaceuticals Inc. continue its uptrendMarket Activity Summary & Fast Exit/Entry Strategy Plans - newser.com
Is Alnylam Pharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Review & Target Return Focused Picks - newser.com
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline - GlobeNewswire Inc.
How to monitor Alnylam Pharmaceuticals Inc. with trend dashboards2025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com
What data driven models say about Alnylam Pharmaceuticals Inc.’s futureTreasury Yields & Fast Exit and Entry Trade Guides - newser.com
What RSI levels show for Alnylam Pharmaceuticals Inc. (DUL) stock2025 Stock Rankings & Long-Term Investment Growth Plans - newser.com
Combining machine learning predictions for Alnylam Pharmaceuticals Inc.2025 Market Sentiment & Stepwise Entry and Exit Trade Signals - newser.com
Tredje AP fonden Has $3.98 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam (ALNY) Dropped from Goldman Sachs Conviction List - GuruFocus
How to recover losses in Alnylam Pharmaceuticals Inc. stock2025 Bull vs Bear & Comprehensive Market Scan Reports - newser.com
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flowsJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Has Alnylam Pharmaceuticals Inc. found a price floorJuly 2025 News Drivers & Weekly High Return Stock Forecasts - newser.com
Sumitomo Life Insurance Co. Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Published on: 2025-11-03 03:21:20 - newser.com
Is Alnylam Pharmaceuticals Inc. stock resilient to inflationJuly 2025 Sentiment & AI Driven Stock Price Forecasts - newser.com
How dovish Fed policy supports Alnylam Pharmaceuticals Inc. (DUL) stock2025 Historical Comparison & Real-Time Stock Entry Alerts - newser.com
Envestnet Asset Management Inc. Buys 23,749 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. reversing from oversold territoryIPO Watch & Verified Technical Trade Signals - newser.com
How risky is Alnylam Pharmaceuticals Inc. (DUL) stock compared to peersEarnings Overview Report & Precise Buy Zone Tips - newser.com
Is it time to cut losses on Alnylam Pharmaceuticals Inc.July 2025 Earnings & Fast Entry and Exit Trade Plans - newser.com
Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.July 2025 Drop Watch & Stepwise Trade Execution Plans - newser.com
What downside risks could hit Alnylam Pharmaceuticals Inc. (DUL) stockOptions Play & Free Community Supported Trade Ideas - newser.com
Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesQuarterly Trade Summary & Community Consensus Trade Signals - newser.com
Alnylam Pharmaceuticals Hits Day Low of $436.51 Amid Price Pressure - Markets Mojo
Alnylam Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year - Yahoo Finance
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Benzinga
ANTIPODES PARTNERS Ltd Sells 36,750 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock vulnerable to rate hikes2025 Technical Overview & High Accuracy Trade Alerts - newser.com
Strs Ohio Has $9.83 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Focus Partners Advisor Solutions LLC Has $263,000 Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Why Alnylam Pharmaceuticals Inc. stock is recommended by analystsJuly 2025 Review & Capital Efficiency Focused Strategies - newser.com
What to do if you’re stuck in Alnylam Pharmaceuticals Inc.Wall Street Watch & Low Drawdown Investment Ideas - newser.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2025 Earnings Call Transcript - Insider Monkey
A Fresh Look at Alnylam Pharmaceuticals (ALNY) Valuation Following Q3 Profit Surge and Upgraded Guidance - simplywall.st
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Oct 02 '25 |
Sale |
452.05 |
8,924 |
4,034,085 |
65,409 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Oct 02 '25 |
Sale |
452.05 |
1,405 |
635,126 |
27,438 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Oct 02 '25 |
Sale |
452.05 |
2,441 |
1,103,451 |
25,231 |
| Garg Pushkal | EVP Chief R&D |
Oct 03 '25 |
Sale |
451.48 |
3,022 |
1,364,387 |
20,221 |
| Garg Pushkal | EVP Chief R&D |
Oct 02 '25 |
Sale |
452.05 |
2,937 |
1,327,675 |
23,243 |
1.19%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):